Home>Topics>Stocks>Dendreon Corporation

Dendreon Corporation

  1. All
  2. Commentary
  1. Dendreon Receives Positive EU Opinion for Provenge; No Change to Fair Value Estimate or Moat Rating

    Commentary

    Fri, 28 Jun 2013

    Dendreon DNDN announced that it received a positive ..... Commission later this year, and we expect Dendreon to announce its commercialization plans ..... rating intact as we remain concerned about Dendreon 's ability to achieve meaningful commercial

  2. Provenge Sales Plummet in Dendreon's First Quarter

    Commentary

    Thu, 9 May 2013

    Dendreon DNDN reported dismal first-quarter results ..... prostate cancer space. Though we believe Dendreon 's first quarter will be a low-water ..... product revenue in the third quarter. Dendreon had $337.3 million in cash and investments

  3. Account Growth and Lower Costs Are Bright Spots in Dendreon's Third Quarter

    Commentary

    Fri, 2 Nov 2012

    deluge of negative developments over the last two years, Dendreon DNDN investors may finally be getting some good news in the firm ..... sequential basis. Despite continued slow Provenge sales traction, Dendreon 's cost-cutting efforts are beginning to take hold. The

  4. We're Substantially Lowering Our Outlook for Dendreon as Provenge Fails to Take Off

    Commentary

    Fri, 10 Aug 2012

    Sales of Dendreon 's DNDN sole marketed product Provenge are ..... downgrading our stewardship score for Dendreon to poor. Provenge's bungled launch ..... appropriate steps to try to right size Dendreon 's capacity to better match demand

  5. Dendreon Announces Large-Scale Restructuring on Heels of Slow Provenge Sales

    Commentary

    Tue, 31 Jul 2012

    Dendreon DNDN reported second-quarter results that ..... earlier this year--has exacerbated Dendreon 's preexisting commercialization challenges ..... trajectory, restructuring efforts should put Dendreon one step closer to profitability. Data

  6. Dendreon Sees Modest Sequential Growth for Provenge in 1Q; Firm Still in Range of Our 2012 Targets

    Commentary

    Tue, 8 May 2012

    Dendreon DNDN reported first-quarter results that ..... keeping our fair value estimate intact. Dendreon reported Provenge sales of $82.0 million ..... sales estimate of around $370 million. Dendreon outlined new efforts aimed at increasing

  7. Dendreon's 4Q Results and Near-Term Outlook Reflect Continued Uncertainty for Provenge

    Commentary

    Mon, 27 Feb 2012

    Dendreon DNDN reported fourth-quarter results and ..... million in the prior-year period, as Dendreon continues to slowly expand the number ..... interest in Merck's MRK Victrelis pushed Dendreon into the black for the quarter ($0

  8. Savient Loses CEO to Dendreon Amid Management Shakeup

    Commentary

    Wed, 1 Feb 2012

    Johnson has resigned to take over as CEO of Dendreon DNDN . Although seeing the Johnson jump ship is concerning for Savient shareholders, Dendreon is a much larger firm and a more high ..... sees weak prospects for Savient. From Dendreon 's perspective, we think the management

  9. Dendreon's Reported Fourth-Quarter Provenge Sales Outperform Expectations

    Commentary

    Thu, 5 Jan 2012

    Dendreon 's DNDN shares have skyrocketed following the firm's announcement that full-year gross revenues from Provenge would come in at approximately

  10. Regeneron Gains FDA Approval for Eylea

    Commentary

    Mon, 21 Nov 2011

    to be learning from the launch experiences of its biotech peers--such as the reimbursement troubles of its biotech peer Dendreon DNDN --to smooth Eylea's initial uptake in the market; the firm has put in place a payment assistance program, including

« Prev12Next »
Content Partners